Streetbeat News

Price Targets

REVG

REV Group's specialty vehicles segment has driven strong earnings, leading to a 74.27% share price increase in the past year. Management's focus on productivity and cost control has resulted in earnings growth outpacing revenue, with a one-year price target of $48.05, a 41% increase. REV's competitive strengths and market leadership in specialty vehicles, particularly fire and ambulance, support its continued profitability and growth potential.

Portfolio Pulse from

February 11, 2025 | 11:15 am

NBIX

Neurocrine Biosciences' stock fell over 3% after three analysts lowered their price targets, despite the company reporting better-than-expected profitability in the fourth quarter.

Portfolio Pulse from

February 10, 2025 | 11:45 pm

DOCS

Doximity, Inc. reported strong Q3 earnings, surpassing management's expectations. The stock has risen 56% since the last analysis, significantly outperforming the S&P 500. An updated DCF valuation suggests a new price target of $90, indicating a 14% upside.

Portfolio Pulse from

February 10, 2025 | 5:15 pm

TSLA

Stifel has lowered its price target for Tesla due to negative public perception of CEO Elon Musk's involvement with the Trump administration, which is seen as a potential obstacle for Tesla sales.

Portfolio Pulse from

February 10, 2025 | 5:00 pm

RGNX

Wall Street analysts have set a consensus price target for Regenxbio (RGNX) that suggests a potential 333% upside. Despite skepticism about the effectiveness of price targets, positive earnings estimate revisions indicate a possible near-term stock price increase.

Portfolio Pulse from

February 10, 2025 | 4:15 pm

ACHR

Wall Street analysts predict a potential 25.61% surge in Archer Aviation (ACHR) stock, based on the mean of analysts' price targets. Despite the mixed reliability of this metric, the consensus on raising earnings estimates suggests a positive outlook.

Portfolio Pulse from

February 10, 2025 | 4:15 pm

ALUR

Analysts predict a significant upside potential of 374.7% for Allurion Technologies, Inc. (ALUR), with strong consensus on raising earnings estimates.

Portfolio Pulse from

February 10, 2025 | 4:15 pm

NXT

Wall Street analysts suggest a 25.3% upside potential for Nextracker (NXT), driven by upward earnings estimate revisions.

Portfolio Pulse from

February 10, 2025 | 4:15 pm

SYRE

Spyre Therapeutics (SYRE) has a consensus price target suggesting a potential 158.9% upside. Despite skepticism about the effectiveness of price targets, positive earnings estimate revisions could indicate a near-term stock price increase.

Portfolio Pulse from

February 10, 2025 | 4:15 pm

CRUS

Wall Street analysts have set an average price target for Cirrus Logic (CRUS) that suggests a potential upside of 29.3%. This optimism is supported by positive trends in earnings estimate revisions, which could lead to a stock price increase.

Portfolio Pulse from

February 10, 2025 | 4:15 pm